Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on November 30, 2020. The registrant is incorporated in California and trades under the symbol OCX on the NYSE American. The filing serves as a Regulation FD disclosure regarding an upcoming investor presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
- Upcoming Event: OncoCyte is scheduled to present at the Piper Sandler Virtual Healthcare Conference on December 1, 2020.
- Topics: The presentation will cover diagnostic tests, pharma services, product development, and future plans.
- Forward-Looking Statements: The filing includes a standard disclaimer that forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated results due to factors detailed in the company's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the company name is OncoCyte Corporation, as the input metadata incorrectly referenced "Insight Molecular Diagnostics Inc."
- Review the attached Exhibit 99.1 (Slide presentation) for the specific details regarding product development and plans mentioned in the filing.
- Consult the most recent Form 10-K or 10-Q for actual financial metrics, as this 8-K contains no financial data.
- Check the "Risk Factors" section of recent periodic reports for details on the uncertainties affecting forward-looking statements.